• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

开始使用肿瘤坏死因子-α抑制剂治疗炎症性肠病和类风湿关节炎的患者侵袭性真菌感染的发病率及危险因素

Incidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor-Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis.

作者信息

Hennessee Ian, Benedict Kaitlin, Bahr Nathan C, Lipner Shari R, Gold Jeremy A W

机构信息

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

出版信息

Clin Infect Dis. 2025 Feb 24;80(2):364-366. doi: 10.1093/cid/ciae444.

DOI:10.1093/cid/ciae444
PMID:39223720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11848264/
Abstract

In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiating tumor necrosis factor-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.

摘要

在一项商业索赔数据库分析中，炎症性肠病或类风湿性关节炎患者中，不到0.5%在开始肿瘤坏死因子-α治疗的1年内发生侵袭性真菌感染（IFI）。组织胞浆菌病是最常见的IFI类型。总体IFI发病率因地区、基础疾病和某些免疫抑制药物的使用情况而异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aee1/11848264/123ba510a5c9/ciae444_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aee1/11848264/123ba510a5c9/ciae444_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aee1/11848264/123ba510a5c9/ciae444_ga.jpg

相似文献

1
Incidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor-Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis.开始使用肿瘤坏死因子-α抑制剂治疗炎症性肠病和类风湿关节炎的患者侵袭性真菌感染的发病率及危险因素
Clin Infect Dis. 2025 Feb 24;80(2):364-366. doi: 10.1093/cid/ciae444.
2
Fungal Infections Associated With TNF-Inhibitors: A 20-Year of a Systematic Review Fungal Infections and TNF-Inhibitors.与肿瘤坏死因子抑制剂相关的真菌感染：20年系统综述 真菌感染与肿瘤坏死因子抑制剂
Mycoses. 2025 Mar;68(3):e70040. doi: 10.1111/myc.70040.
3
Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics?肿瘤坏死因子-α抑制剂治疗炎症性肠病并发组织胞浆菌病：继续使用生物制剂安全吗？
Dig Dis Sci. 2021 Jan;66(1):190-198. doi: 10.1007/s10620-020-06181-x. Epub 2020 Mar 7.
4
Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.在使用肿瘤坏死因子-α 拮抗剂治疗过程中发生了分枝杆菌病。
Eur Respir J. 2014 Nov;44(5):1289-95. doi: 10.1183/09031936.00063514. Epub 2014 Aug 7.
5
Low incidence of invasive fungal infection and risk factors in a large observational cohort of patients initiating tumor necrosis factor-alpha inhibitors for dermatologic conditions.一大群开始使用肿瘤坏死因子-α抑制剂治疗皮肤病的患者中侵袭性真菌感染的低发病率及危险因素
J Am Acad Dermatol. 2024 Sep;91(3):510-513. doi: 10.1016/j.jaad.2024.03.046. Epub 2024 Apr 27.
6
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.丹麦一项全国性基于人群的队列研究：抗肿瘤坏死因子-α 治疗与炎症性肠病、类风湿关节炎或银屑病且既往有癌症患者的复发性或新发原发性癌症。
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):276-284. doi: 10.1016/S2468-1253(19)30362-0. Epub 2019 Dec 10.
7
Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis.评估肿瘤坏死因子-α抑制剂治疗类风湿关节炎和青少年类风湿关节炎后新发炎症性肠病的可能性。
Rheumatol Int. 2015 Apr;35(4):661-8. doi: 10.1007/s00296-014-3133-9. Epub 2014 Sep 17.
8
Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy.炎症性肠病相关的抗 TNF 抗体治疗的地方性真菌感染。
Inflamm Bowel Dis. 2013 Oct;19(11):2490-500. doi: 10.1097/MIB.0b013e31828f1fba.
9
Estimating cancer risk in immune-mediated inflammatory diseases exposed to varying doses of tumour necrosis factor inhibitors.评估暴露于不同剂量肿瘤坏死因子抑制剂的免疫介导炎症性疾病中的癌症风险。
J Gastroenterol. 2025 Mar;60(3):285-293. doi: 10.1007/s00535-024-02190-z. Epub 2024 Dec 5.
10
Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.接受肿瘤坏死因子-α抑制剂治疗后葡萄膜黑色素瘤患者的临床和组织学发现。
Mayo Clin Proc. 2014 Nov;89(11):1481-6. doi: 10.1016/j.mayocp.2014.08.012. Epub 2014 Nov 3.

引用本文的文献

1
Case Report: Facial Malassezia folliculitis following infliximab treatment in Crohn's disease.病例报告：克罗恩病患者接受英夫利昔单抗治疗后出现面部马拉色菌毛囊炎
Front Immunol. 2025 Aug 12;16:1611893. doi: 10.3389/fimmu.2025.1611893. eCollection 2025.
2
Exploring new drug treatment targets for immune related bone diseases using a multi omics joint analysis strategy.使用多组学联合分析策略探索免疫相关骨疾病的新药治疗靶点。
Sci Rep. 2025 Mar 27;15(1):10618. doi: 10.1038/s41598-025-94053-7.
3
Evolving Epidemiology, Improving Diagnostic Tests and Their Importance for the Correct Diagnosis of Histoplasmosis.

本文引用的文献

1
Low incidence of invasive fungal infection and risk factors in a large observational cohort of patients initiating tumor necrosis factor-alpha inhibitors for dermatologic conditions.一大群开始使用肿瘤坏死因子-α抑制剂治疗皮肤病的患者中侵袭性真菌感染的低发病率及危险因素
J Am Acad Dermatol. 2024 Sep;91(3):510-513. doi: 10.1016/j.jaad.2024.03.046. Epub 2024 Apr 27.
2
Incidence of histoplasmosis in patients receiving TNF-alpha inhibitors: A systematic review and meta-analysis.接受 TNF-α 抑制剂治疗的患者中组织胞浆菌病的发病率：系统评价和荟萃分析。
Medicine (Baltimore). 2023 Dec 8;102(49):e36450. doi: 10.1097/MD.0000000000036450.
3
不断演变的流行病学、改进的诊断测试及其对组织胞浆菌病正确诊断的重要性。
J Fungi (Basel). 2025 Mar 4;11(3):196. doi: 10.3390/jof11030196.
4
Biology, Immunology, Epidemiology, and Therapy of Fungal Infections: A Themed Issue Dedicated to Professor David A. Stevens: Editorial.真菌感染的生物学、免疫学、流行病学与治疗：献给大卫·A·史蒂文斯教授的专题：编者按
J Fungi (Basel). 2025 Feb 25;11(3):179. doi: 10.3390/jof11030179.
5
Multi-omic biomarkers associated with multiple sclerosis: from Mendelian randomization to drug prediction.与多发性硬化症相关的多组学生物标志物：从孟德尔随机化到药物预测
Sci Rep. 2025 Mar 19;15(1):9421. doi: 10.1038/s41598-025-94303-8.
Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor Necrosis Factor-Alpha Inhibitors in Patients With Inflammatory Bowel Disease.
在炎症性肠病患者中，皮质类固醇比肿瘤坏死因子-α抑制剂更易增加侵袭性真菌感染的风险。
Crohns Colitis 360. 2023 Feb 19;5(2):otad010. doi: 10.1093/crocol/otad010. eCollection 2023 Apr.
4
Immune responses to human fungal pathogens and therapeutic prospects.人类真菌病原体的免疫反应和治疗前景。
Nat Rev Immunol. 2023 Jul;23(7):433-452. doi: 10.1038/s41577-022-00826-w. Epub 2023 Jan 4.
5
Fungal Infections Potentiated by Biologics.生物制剂引发的真菌感染。
Infect Dis Clin North Am. 2020 Jun;34(2):389-411. doi: 10.1016/j.idc.2020.02.010. Epub 2020 Apr 23.
6
Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.组织胞浆菌病并发肿瘤坏死因子-α阻滞剂治疗：98例回顾性分析
Clin Infect Dis. 2015 Aug 1;61(3):409-17. doi: 10.1093/cid/civ299. Epub 2015 Apr 13.
7
Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.抗肿瘤坏死因子-α治疗炎症性肠病中的机会性感染：随机对照试验的荟萃分析。
Am J Gastroenterol. 2013 Aug;108(8):1268-76. doi: 10.1038/ajg.2013.138. Epub 2013 May 7.
8
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.肿瘤坏死因子-α拮抗剂的起始治疗与自身免疫性疾病患者感染住院风险。
JAMA. 2011 Dec 7;306(21):2331-9. doi: 10.1001/jama.2011.1692. Epub 2011 Nov 6.
9
Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy.接受肿瘤坏死因子-α抑制剂治疗患者的地方性真菌感染
Drugs. 2009 Jul 30;69(11):1403-15. doi: 10.2165/00003495-200969110-00002.
10
Fungal infections complicating tumor necrosis factor alpha blockade therapy.肿瘤坏死因子α阻断治疗并发真菌感染。
Mayo Clin Proc. 2008 Feb;83(2):181-94.